Sarepta halts its golodirsen Duchenne MD study in UK after patient experiences adverse event
Sarepta said this morning that it has halted dosing its Duchenne muscular dystrophy drug golodirsen at all its UK sites after one of the patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
